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It is well recognized that seafood omega 3 fatty acids (n-3 PUFA) have an important role in the 
prevention of several disorders, in particular coronary heart disease by lowering blood pressure and heart 
rate variability; reducing serum triglycerides, thrombotic tendency, inflammation and arrhythmias. Moreover, 
the scarcity of some fish species used for fish oil production, pointed out the need of new n-3 PUFA sources. 
Thus, Diacronema vlkianum a marine microalgae is a new promising source of these fatty acids. 
Nevertheless, dietary use cannot be established before the bioavailability evaluation.  
The aim of the present study was evaluating the incorporation of the main n-3 PUFA in subcutaneous 
and visceral fat and consequently their bioavailability. 
Experiment: 14/15 male Wistar rats/group respectively were orally administered, by gavage, with 0 (control) 
or 100mg/Kg/day single dose of microalgae suspended in water. Animals were daily monitored. At the 
beginning and after two months animals were sacrificed and tissues were collected and preserved at -80ºC 
for subsequent fatty acid profiling GC-FID. Statistical analysis of the data obtained consisted of two-sample 
assuming unequal variances t-test t-student’s. Comparisons were made between microalgae and control 
group, after two months of experiment. Differences were considered significant at P <0.05.  
Discussion: D. vlkianum main n-3 PUFA were 20:5n-3 (EPA), 22:5n-3 (DPA) and 22:6n-3 (DHA) used as 
biomarkers of microalgae tissue incorporation. Obtained results showed that EPA presented in subcutaneous 
fat a high significant level in supplemented group compared with control (0.21%±0.04 vs 0.06%±0.05). 
Moreover n-3 PUFA also presented a high level in treated rats faced to control (2.48%±0.21 vs 1.97%±0.47). 
In the case of visceral fat, microalgae group had increased levels of DPA in comparison to control (0.14%± 
0.01 and 0.05%± 0.08, respectively). Deposition rate values showed a higher incorporation of EPA and DPA 
in visceral fat comparatively to subcutaneous fat in supplemented group. In addition, this in vivo model allow 
concluding that consuming microalgae for two months presented more beneficial pronounced changes in 
visceral than in subcutaneous fat. The increase of EPA in subcutaneous and DPA in visceral fat supports the 
benefits of microalgae supplementation in the prevention of CHD. Thus, the bioavailability of n-3 PUFA of 
microalgae was confirmed. 
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